The Respiratory Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Respiratory Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Respiratory Failure. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Respiratory Failure - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Respiratory Failure and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Respiratory Failure by nine companies/universities/institutes. The top development phase for Respiratory Failure is phase ii with six drugs in that stage. The Respiratory Failure pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Respiratory Failure pipeline products market are: Reven, Asklepion Pharmaceuticals and AstraZeneca.

The key targets in the Respiratory Failure pipeline products market include Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA), Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R), and L-Citrulline.

The key mechanisms of action in the Respiratory Failure pipeline product include Granulocyte Colony Stimulating Factor Receptor (CD114 or GCSFR or CSF3R) Antagonist with one drug in Phase II. The Respiratory Failure pipeline products include six routes of administration with the top ROA being Intravenous and five key molecule types in the Respiratory Failure pipeline products market including Small Molecule, and Monoclonal Antibody.

Respiratory Failure overview

The respiratory system allows gas exchange between the environment and the body, facilitating the process of aerobic metabolism. Specifically, the respiratory system provides oxygen and removes carbon dioxide from the body. The inability of the respiratory system to perform either or both of these tasks results in respiratory failure. Respiratory failure can be classified based on chronicity: acute, chronic, and acute on chronic.

For a complete picture of Respiratory Failure’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.